Drug Interaction Report

The safety, immunogenicity, and efficacy of SARS-CoV-2 (COVID-19) vaccines have not been evaluated during concomitant administration of tixagevimab and cilgavimab. However, no safety concerns were identified in limited data from the PROVENT trial, where patients were able to elect to receive COVID-19 vaccination after administration of tixagevimab and cilgavimab. Additionally, pharmacokinetic modeling did not reveal any clinically relevant impact on the clearance of these anti-SARS-CoV-2 monoclonal antibodies after receipt of a COVID-19 vaccination. The United States Food and Drug Administration (FDA) revised its emergency use authorization for tixagevimab co-packaged with cilgavimab (Evusheld) on January 26, 2023, to limit the use of this product to when the combined frequency of non-susceptible SARS-CoV-2 variants nationally is less than or equal to 90%. Current guidelines should be consulted for recommended timing of vaccination in relation to the administration of tixagevimab and cilgavimab.